This is the authors' abstract. We don't add key points for this paper.
PURPOSE: The objective of this article is to discuss the pharmacology, side effects, and clinical application of vasoactive therapy in the management of adult septic shock. SUMMARY: Sepsis is one of the most common reasons for admission to an intensive care unit with the incidence estimated to be greater than 750 000 cases per year in the United States. Clinicians should understand the basic pharmacology of available vasoactive agents to allow for routine and complex management of septic shock. CONCLUSION: While advances in research, identification, and early implementation of best practices for the treatment of sepsis has reduced mortality, rates remain high. Vasopressors and inotropes remain part of the core therapeutic modalities of sepsis management. Norepinephrine is the first-line vasopressor of choice for septic shock, though secondary vasopressors can be used depending on the patient's circumstances.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dalimonte et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: